pH-Responsive Artesunate Polymer Prodrugs with Enhanced Ablation Effect on Rodent Xenograft Colon Cancer.
Animals
Artesunate
/ chemistry
Colonic Neoplasms
/ drug therapy
Drug Delivery Systems
Drug Liberation
Female
Humans
Hydrogen-Ion Concentration
Hydrophobic and Hydrophilic Interactions
Mice, Inbred BALB C
Micelles
Oxazoles
/ chemistry
Polymers
/ chemistry
Prodrugs
/ chemistry
Xenograft Model Antitumor Assays
artesunate
micelles
pH responsive
poly(2-ethyl-2-oxazoline)
poly(β-amino ester)
polymer prodrug
Journal
International journal of nanomedicine
ISSN: 1178-2013
Titre abrégé: Int J Nanomedicine
Pays: New Zealand
ID NLM: 101263847
Informations de publication
Date de publication:
2020
2020
Historique:
received:
12
12
2019
accepted:
02
03
2020
entrez:
28
3
2020
pubmed:
28
3
2020
medline:
3
7
2020
Statut:
epublish
Résumé
In this study, pH-sensitive poly(2-ethyl-2-oxazoline)-poly(lactic acid)-poly(β-amino ester) (PEOz-PLA-PBAE) triblock copolymers were synthesized and were conjugated with an antimalaria drug artesunate (ART), for inhibition of a colon cancer xenograft model. The as-prepared polymer prodrugs are tended to self-assemble into polymeric micelles in aqueous milieu, with PEOz segment as hydrophilic shell and PLA-PBAE segment as hydrophobic core. The pH sensitivity of the as-prepared copolymers was confirmed by acid-base titration with p The pH-responsive artesunate polymer prodrugs are promising candidates for colon cancer adjuvant therapy.
Identifiants
pubmed: 32214810
doi: 10.2147/IJN.S242032
pii: 242032
pmc: PMC7083641
doi:
Substances chimiques
Micelles
0
Oxazoles
0
Polymers
0
Prodrugs
0
Artesunate
60W3249T9M
2-ethyl-2-oxazoline
B8CD92T4P5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1771-1786Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2020 Hao et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Redox Biol. 2017 Apr;11:254-262
pubmed: 28012440
Drug Deliv. 2013 Apr-May;20(3-4):127-33
pubmed: 23731485
Vascul Pharmacol. 2007 Aug-Sep;47(2-3):131-8
pubmed: 17581794
Cancer Res. 2000 Mar 15;60(6):1645-53
pubmed: 10749135
Chem Biol Interact. 2010 Apr 15;185(1):42-52
pubmed: 20144594
Bioconjug Chem. 2018 Dec 19;29(12):4050-4061
pubmed: 30404436
Int J Pharm. 2004 Jun 18;278(1):1-23
pubmed: 15158945
Int J Biol Macromol. 2019 Jul 15;133:495-502
pubmed: 31004634
Annu Rev Biochem. 1986;55:663-700
pubmed: 2874766
Crit Rev Toxicol. 2010 May;40(5):405-21
pubmed: 20158370
J Clin Oncol. 2013 Jun 1;31(16):1913-6
pubmed: 23630214
ACS Appl Mater Interfaces. 2017 Mar 1;9(8):6916-6930
pubmed: 28186394
J Control Release. 2000 Mar 1;65(1-2):271-84
pubmed: 10699287
Nanoscale. 2012 May 21;4(10):3095-104
pubmed: 22535210
J Pharm Sci. 2015 May;104(5):1815-24
pubmed: 25753991
Food Chem Toxicol. 2013 Oct;60:269-76
pubmed: 23911803
Int J Pharm. 2019 May 1;562:162-171
pubmed: 30902709
J Phys Chem B. 2008 Dec 25;112(51):16490-6
pubmed: 19367861
Anticancer Drugs. 2014 Jul;25(6):652-62
pubmed: 24518199
Int J Clin Exp Med. 2015 Dec 15;8(12):22045-52
pubmed: 26885179
Anticancer Res. 2011 Jan;31(1):1-10
pubmed: 21273574
Mol Carcinog. 2017 Jan;56(1):75-93
pubmed: 26878598
ACS Appl Mater Interfaces. 2018 Feb 21;10(7):6155-6167
pubmed: 29378409
Nanomedicine (Lond). 2017 Jan;12(2):147-164
pubmed: 27854565
Mol Aspects Med. 2010 Feb;31(1):1-20
pubmed: 19698742
Cancer Chemother Pharmacol. 2010 Apr;65(5):895-902
pubmed: 19690861
Oncotarget. 2014 Jun 30;5(12):4118-28
pubmed: 24948357
Int J Mol Sci. 2014 Aug 15;15(8):14298-312
pubmed: 25196524
Nat Nanotechnol. 2011 Oct 23;6(12):815-23
pubmed: 22020122
J Control Release. 2003 Feb 21;87(1-3):33-47
pubmed: 12618021
Free Radic Biol Med. 2015 Nov;88(Pt A):10-7
pubmed: 26073122
Biochimie. 2014 Dec;107 Pt B:338-49
pubmed: 25308836
Small. 2017 Aug;13(29):
pubmed: 28594473
Nanoscale Res Lett. 2017 Dec;12(1):403
pubmed: 28610396
Acta Biomater. 2015 Apr;17:182-92
pubmed: 25612838
Tumour Biol. 2014 Jun;35(6):5307-14
pubmed: 24519064
Curr Med Chem. 2017;24(15):1537-1557
pubmed: 28079003
Molecules. 2011 Dec 19;16(12):10556-69
pubmed: 22183882
Drug Deliv. 2017 Nov;24(1):1124-1138
pubmed: 28789585
Biochim Biophys Acta. 2003 Oct 31;1617(1-2):52-61
pubmed: 14637019
Proteomics Clin Appl. 2015 Feb;9(1-2):64-71
pubmed: 25311658
Biomacromolecules. 2016 Nov 14;17(11):3640-3647
pubmed: 27641634
Phytomedicine. 2017 Dec 15;37:58-61
pubmed: 29174651
Clin Cancer Res. 2016 Feb 1;22(3):540-5
pubmed: 26660517
Br J Pharmacol. 2009 Apr;156(7):1054-66
pubmed: 19298255
Cancer Res. 2008 Jun 1;68(11):4347-51
pubmed: 18519695
Nanomedicine (Lond). 2018 Oct;13(20):2611-2627
pubmed: 30334683
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Int Immunopharmacol. 2012 Jan;12(1):312-4
pubmed: 22051974
Apoptosis. 2017 Dec;22(12):1487-1509
pubmed: 29067538
Nanomedicine (Lond). 2017 Apr;12(7):811-817
pubmed: 28322116
Exp Cell Res. 2016 Oct 1;347(2):251-60
pubmed: 27327234
Drug Deliv. 2019 Dec;26(1):300-308
pubmed: 30895837
Life Sci. 2016 Jul 15;157:1-11
pubmed: 27234895
Bioimpacts. 2013;3(4):149-62
pubmed: 24455478